<SEC-DOCUMENT>0001193125-25-004044.txt : 20250110
<SEC-HEADER>0001193125-25-004044.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110063011
ACCESSION NUMBER:		0001193125-25-004044
CONFORMED SUBMISSION TYPE:	425
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ikena Oncology, Inc.
		CENTRAL INDEX KEY:			0001835579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		425
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40287
		FILM NUMBER:		25520252

	BUSINESS ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-343-8292

	MAIL ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ikena Oncology, Inc.
		CENTRAL INDEX KEY:			0001835579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		425

	BUSINESS ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-343-8292

	MAIL ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
</SEC-HEADER>
<DOCUMENT>
<TYPE>425
<SEQUENCE>1
<FILENAME>d189731d425.htm
<DESCRIPTION>425
<TEXT>
<HTML><HEAD>
<TITLE>425</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Filed by Ikena Oncology, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">pursuant to Rule 425 under the Securities Act of 1933 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">and deemed filed pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">under the Securities Exchange Act of 1934 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Subject Company: Ikena Oncology, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Commission File No.: <FONT STYLE="white-space:nowrap">001-40287</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Date: January&nbsp;10, 2025 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g189731g0110002939048.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inmagene Reports Positive Topline Results of <FONT STYLE="white-space:nowrap">IMG-007,</FONT> a Nondepleting
Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Atopic Dermatitis </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>A <FONT STYLE="white-space:nowrap">4-week</FONT> treatment with
<FONT STYLE="white-space:nowrap">IMG-007</FONT> resulted in a mean reduction in eczema area and severity index (EASI) of 77% and <FONT STYLE="white-space:nowrap">EASI-75</FONT> response of 54%, at week 16</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Durable inhibition of inflammatory markers was observed for up to 24 weeks</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">IMG-007&#146;s</FONT> subcutaneous (SC) formulation demonstrated an extended
half-life of approximately 35 days</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">IMG-007</FONT> was overall well-tolerated with no reports of pyrexia or
chills</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">IMG-007&#146;s</FONT> ability to block OX40/OX40L signaling without depleting
T cells, coupled with an extended half-life, underscores its potential for a differentiated clinical profile and convenient dosing regimens</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Initiation of a Phase 2b dose-finding study with <FONT STYLE="white-space:nowrap">IMG-007&#146;s</FONT> SC
formulation in patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> atopic dermatitis (AD) is planned for Q1 2025</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA, January&nbsp;9, 2025 &#150; Inmagene Biopharmaceuticals (&#147;Inmagene&#148; or the &#147;Company&#148;), a clinical-stage biotechnology
company developing innovative and differentiated therapies for immunological and inflammatory (I&amp;I) diseases, today reports additional positive topline results from the Phase 2a trial of <FONT STYLE="white-space:nowrap">IMG-007</FONT> in
patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> AD, along with the results of a Phase 1 trial of <FONT STYLE="white-space:nowrap">IMG-007&#146;s</FONT> SC formulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#147;IMG-007</FONT> is the only clinical-stage monoclonal antibody which specifically blocks OX40/OX40L signaling in both
blood and tissues without depleting T cells,&#148; said Jonathan Wang, founder, Chairman and CEO of Inmagene, <FONT STYLE="white-space:nowrap">&#147;IMG-007&#146;s</FONT> extended half-life combined with the sustained efficacy demonstrated will
enable us to explore long dosing intervals, such as every 24 weeks, for maintenance therapy in AD and other potential indications.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">IMG-007</FONT> is a nondepleting anti-OX40 monoclonal antibody (mAb) engineered to have a silenced antibody-dependent cellular cytotoxicity (ADCC) function to minimize potential safety risks, and a prolonged half-life to
enable potentially less frequent dosing regimens. The Phase 2a open-label trial (NCT05984784) of 13 patients across centers in the U.S. and Canada evaluated the safety, pharmacokinetics (PK) and efficacy of intravenous
<FONT STYLE="white-space:nowrap">(IV)&nbsp;IMG-007</FONT> in adult patients with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> AD. Similar to the <U>interim results reported in May 2024</U>,
administration of three doses of <FONT STYLE="white-space:nowrap">IMG-007</FONT> at Week 0, 2, and 4 resulted in marked and durable clinical activity as assessed by EASI and other outcome measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After 4 weeks of treatment with <FONT STYLE="white-space:nowrap">IMG-007,</FONT> the mean percent change of EASI and the
<FONT STYLE="white-space:nowrap">EASI-75</FONT> response at Week 16 were 77% and 54%, respectively, which are within the range shown by other investigational OX40/OX40L-targeting mAbs with longer duration (at least 16 weeks) of treatments. In
addition, durable inhibition of serum inflammatory markers of diverse T helper (Th) cells, including Th1, Th2 and Th17 cells, was observed for up to 24 weeks. <FONT STYLE="white-space:nowrap">IMG-007</FONT> was generally well-tolerated, with no
serious adverse events (SAEs), no adverse events (AEs) leading to treatment discontinuation, and no treatment-related AEs. There were no reports of pyrexia or chills. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Separately, the Company conducted a Phase 1 study (NCT06304740) to evaluate the safety and PK of <FONT
STYLE="white-space:nowrap">IMG-007&#146;s</FONT> SC formulation in 16 healthy adults. Overall, the PK profile of the SC formulation is consistent with that of the IV formulation. At the projected therapeutic dose level, the serum concentrations were
maintained above the level needed for blocking OX40/OX40L signaling in circulation for the entire <FONT STYLE="white-space:nowrap">follow-up</FONT> period of 18 weeks. A single SC dose of <FONT STYLE="white-space:nowrap">IMG-007</FONT> demonstrated
a mean terminal half-life of 34.7 days, which is substantially longer than that of other OX40/OX40L mAbs in clinical development. The <FONT STYLE="white-space:nowrap">IMG-007</FONT> SC formulation exhibited a well-tolerated safety profile. Injection
site reactions (ISRs), including injection site erythema, pain and pruritus, were the most commonly reported AEs and occurred more frequently in the placebo group (75%) than the <FONT STYLE="white-space:nowrap">IMG-007</FONT> group (25%). All
reported ISRs were mild. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The positive topline results from the Phase 2a trial of <FONT STYLE="white-space:nowrap">IMG-007</FONT> in patients with
AD are exciting. The robust observed clinical activity and biomarker data that resulted from a short <FONT STYLE="white-space:nowrap">4-week</FONT> treatment, as well as the well-tolerated safety profile, suggest that the ADCC silencing of <FONT
STYLE="white-space:nowrap">IMG-007</FONT> has retained desired biological activity of OX40 blockade while improving the tolerability,&#148; said Yufang Lu, M.D., Ph.D., Chief Medical Officer of Inmagene. &#147;AD is a chronic relapsing disease that
requires long-term management, and currently approved biologics require frequent injections, every 2 or 4 weeks. The extended half-life of <FONT STYLE="white-space:nowrap">IMG-007</FONT> SC formulation coupled with a favorable tolerability profile
would potentially allow for <FONT STYLE="white-space:nowrap">IMG-007</FONT> to provide differentiated dosing regimens in the long-term treatment of AD.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inmagene is planning to initiate a Phase 2b dose-finding study with <FONT STYLE="white-space:nowrap">IMG-007&#146;s</FONT> SC formulation in patients with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> AD in Q1 2025. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inmagene </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory (I&amp;I) diseases. The
company&#146;s highly differentiated clinical-stage pipeline has multiple candidates with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> potential. The lead asset
<FONT STYLE="white-space:nowrap">IMG-007,</FONT> a nondepleting anti-OX40 mAb, is in Phase 2 development. <FONT STYLE="white-space:nowrap">IMG-004,</FONT> a <FONT STYLE="white-space:nowrap">non-covalent</FONT> reversible BTK inhibitor with an
extended half-life and pharmacodynamic effect, enabling its potential for once-daily dosing, is ready for Phase 2 development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information,
please visit <U>www.inmagenebio.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">IMG-007</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">IMG-007</FONT> is a humanized <FONT STYLE="white-space:nowrap">non-depleting</FONT> anti-OX40 IgG1 mAb with a silenced ADCC
function and an extended half-life. The OX40-OX40L axis is important in T cell activation, expansion, and survival, thereby playing an important role in the pathogenesis of a spectrum of I&amp;I diseases. In nonclinical studies, <FONT
STYLE="white-space:nowrap">IMG-007</FONT> potently blocked the signaling between OX40 and OX40L. <FONT STYLE="white-space:nowrap">IMG-007&#146;s</FONT> SC formulation has demonstrated a half-life of 34.7 days which would support the potential for
competitive dose regimens. It is in Phase 2 clinical development. <FONT STYLE="white-space:nowrap">IMG-007</FONT> was originally discovered by HUTCHMED. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without
limitation, statements regarding: the potential benefits of <FONT STYLE="white-space:nowrap">IMG-007,</FONT> including its potential to provide a differentiated clinical profile and convenient dosing regimens, its ADCC function potentially improving
<FONT STYLE="white-space:nowrap">IMG-007&#146;s</FONT> tolerability profile and retaining desired biological activity of OX40 blockage and its prolonged half-life enabling potentially less frequent dosing regimen; the planned Phase 2b dose-finding
study with <FONT STYLE="white-space:nowrap">IMG-007&#146;s</FONT> SC formulation in patients with moderate to severe AD and the timing thereof; the Company&#146;s plans to explore the potential for long dosing intervals for <FONT
STYLE="white-space:nowrap">IMG-007</FONT> for maintenance therapy in AD and other potential indications; the Company&#146;s highly differentiated clinical-stage pipeline having multiple candidates with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> potential; and <FONT STYLE="white-space:nowrap">IMG-004</FONT> being ready for Phase 2 development. These statements are subject to a number of risks, uncertainties and assumptions, including,
but not limited to: preliminary results may not be indicative of results that may be observed in the future; the timing and success of clinical trials and potential safety and other complications thereof; there have been no <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> trials conducted comparing <FONT STYLE="white-space:nowrap">IMG-007</FONT> to other investigational OX40/OX40L-targeting mAbs with longer duration of treatments;
the uncertainties associated with the Company&#146;s platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and
completion of clinical trials; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical
programs being developed and anticipated to be developed; risks related to the inability of the Company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs, including additional capital
from the proposed merger with Ikena Oncology, Inc. (Ikena) and the concurrent private placement; the risk that the conditions to closing of the proposed merger and concurrent private placement are not satisfied and other risks related to the timing,
approvals, consummation and anticipated benefits of the proposed merger. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. You
should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Inmagene expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further information, please contact: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inmagene: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anna Vardanyan, MD, PhD </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVP of Corporate and Business
Development </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>public.relations@inmagenebio.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bruce Mackle </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Advisors, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>bmackle@lifesciadvisors.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication
relates to the proposed merger transaction involving Ikena and Inmagene and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed merger, Ikena will file relevant materials with the U.S.
Securities and Exchange Commission (&#147;SEC&#148;), including a registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the &#147;Form <FONT STYLE="white-space:nowrap">S-4&#148;)</FONT> that will contain a proxy statement (the
&#147;Proxy Statement&#148;) and prospectus. This communication is not a substitute for the Form <FONT STYLE="white-space:nowrap">S-4,</FONT> the Proxy Statement or for any other document that Ikena may file with the SEC and or send to Ikena&#146;s
stockholders in connection with the proposed merger. Ikena, Inmagene, and their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies from Ikena&#146;s stockholders with respect to
the proposed merger under the rules of the SEC. Information about the directors and executive officers of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ikena is set forth in its Schedule 14A, which was filed with the SEC on April&nbsp;26, 2024, and in subsequent documents filed with the SEC. Additional information regarding the persons who may
be deemed participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form <FONT STYLE="white-space:nowrap">S-4,</FONT> the Proxy Statement and
other relevant materials to be filed with the SEC when they become available. You may obtain free copies of this document as described below. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF IKENA ARE URGED TO READ THE FORM <FONT
STYLE="white-space:nowrap">S-4,</FONT> THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT IKENA, THE PROPOSED MERGER AND RELATED
MATTERS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
communication does not constitute an offer to sell or the solicitation of an offer to buy any securities nor a solicitation of any vote or approval with respect to the proposed merger or otherwise. No offering of securities shall be made except by
means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act and otherwise in accordance with applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional
Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and security holders will be able to obtain free copies of the Form
<FONT STYLE="white-space:nowrap">S-4,</FONT> the Proxy Statement and other documents filed by Ikena with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed by Ikena with the SEC will also be
available free of charge on Ikena&#146;s website at www.ikenaoncology.com, or by contacting Ikena&#146;s Investor Relations at rcohen@ikenaoncology.com. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g189731g0110002939048.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g189731g0110002939048.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  K +4# 2(  A$! Q$!_\0
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M,A<,,CJ.*+.UPN6Z*@NKRUL8&GN[F&WA7@R2N$4?B:S_ /A*O#W_ $'=,_\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
